Research Paper Volume 15, Issue 23 pp 14333—14371

Figure 7. Immunotherapy response prediction of the ADPS. (A) Kaplan-Meier survival curves of the ADPS regarding OS in the IMvigor210 cohort. (B) Differences in ADPS among immunotherapy responses in the Imvigor210 cohort. (C) Distribution of immunotherapy responses among ADPS groups in the Imvigor210 cohort. (D) Prognostic differences between ADPS groups in early stage (stage I+II) patients in the Imvigor210 cohort. (E) Prognostic differences between ADPS groups in advanced stage (stage III+IV) patients in the Imvigor210 cohort. (F) Kaplan-Meier survival curves of the ADPS regarding OS in the GSE78220 cohort. (G) Differences in ADPS among immunotherapy responses in the GSE78220 cohort. (H) Distribution of immunotherapy responses among ADPS groups in the GSE78220 cohort. (I) Boxplot of relative expression levels at immune checkpoints between the high and low ADPS patients. (J) Boxplot of TIDE score between the high and low ADPS patients. (K) The relationship between the TIDE score and ADPS. (L) Contingency table between immunotherapy responses and ADPS groups based on TIDE algorithm. (M) Submap analysis of the two groups and 47 pretreated patients with comprehensive immunotherapy annotations. In submap analysis, a smaller p-value indicated a greater similarity of paired expression profiles. ^*p < 0.05; ^**p < 0.01; ^***p < 0.001. Abbreviation: ns: not significant.